• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

COMT Gene Record

  • Summary
  • Interactions
  • Claims
  • COMT 1312 Druggable Genome

    Alternate Names:

    1312
    CATECHOL-O-METHYLTRANSFERASE
    COMT
    HEL-S-98n
    116790
    2228
    ENSG00000093010
    OTTHUMG00000150529
    P21964
    COMT_HUMAN
    PA117
    Catechol O-methyltransferase
    CATECHOL-O-METHYL-TRANSFERASE
    T76904

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:2.1.1.6
    Target Main Class Enzymes
    Target Subclass 2.1.1.6
    Gene Biotype PROTEIN_CODING
    (3 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry
    Stocchi et al., 2006, Utility of tolcapone in fluctuating Parkinson's disease., Clin Interv Aging
    Truong, 2009, Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease., Clin Interv Aging
    Ries et al., 2010, Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study., Clin Neuropharmacol
    Kaakkola, 2000, Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease., Drugs
    Tai et al., 2002, Catechol-O-methyltransferase and Parkinson's disease., Acta Med. Okayama
    Keating et al., 2005, Tolcapone: a review of its use in the management of Parkinson's disease., CNS Drugs
    Ruottinen et al., 1998, COMT inhibition in the treatment of Parkinson's disease., J. Neurol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Apud et al., 2007, Tolcapone improves cognition and cortical information processing in normal human subjects., Neuropsychopharmacology
    Forsberg et al., 2003, Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat., J. Pharmacol. Exp. Ther.
    Guay, 1999, Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease., Pharmacotherapy
    Myer NM et al., 2018, Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD., Mol Psychiatry
    Park S et al., 2014, Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea., J Psychopharmacol
    Yatsuga C et al., 2014, No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children., Brain Dev
    Contini V et al., 2012, No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD., J Clin Psychopharmacol
    Green T et al., 2011, The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome., J Child Adolesc Psychopharmacol
    Salatino-Oliveira A et al., 2011, Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder., Biol Psychiatry
    Cheon KA et al., 2008, Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder., Int Clin Psychopharmacol
    Kereszturi E et al., 2008, Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children., Am J Med Genet B Neuropsychiatr Genet
    Corvol JC et al., 2011, The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial., Ann Neurol
    Najib, 2001, Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease., Clin Ther
    Brooks et al., 2003, Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study., J. Neurol. Neurosurg. Psychiatr.
    Chong et al., 2000, Entacapone., Ann Pharmacother
    Holm et al., 1999, Entacapone. A review of its use in Parkinson's disease., Drugs
    Poewe et al., 2002, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)., Acta Neurol. Scand.
    Duan L et al., 2020, Association of <i>COMT</i> Gene Polymorphisms with Response to Methadone Maintenance Treatment Among Chinese Opioid-Dependent Patients., Genet Test Mol Biomarkers
    Aubrun F et al., 2018, Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study., Eur J Anaesthesiol
    Matic M et al., 2017, Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement., Pharmacogenomics
    Hronová K et al., 2016, Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome., Physiol Res
    Elens L et al., 2016, Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation., Ther Drug Monit
    De Gregori M et al., 2016, Human Genetic Variability Contributes to Postoperative Morphine Consumption., J Pain
    Candiotti KA et al., 2014, Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain., Anesth Analg
    Matic M et al., 2014, Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype., Pharmacogenomics
    Cargnin S et al., 2013, An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans., J Pain
    De Gregori M et al., 2013, Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain., Eur J Clin Pharmacol
    Landau R et al., 2013, The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia., Anesth Analg
    Klepstad P et al., 2011, Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients., Pain
    Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
    Scott LJ, 2016, Opicapone: A Review in Parkinson's Disease., Drugs
    Tardy B et al., 2006, Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin., Blood
    Choi HD et al., 2015, Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis., Pharmacogenomics
    Sun H et al., 2012, Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy., J Neural Transm (Vienna)
    Munafò MR et al., 2008, Association of COMT Val108/158Met genotype with smoking cessation., Pharmacogenet Genomics
    Beuten J et al., 2006, Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations., Neuropsychopharmacology
    David SP et al., 2002, No association between functional catechol O-methyl transferase 1947A&gt;G polymorphism and smoking initiation, persistent smoking or smoking cessation., Pharmacogenetics
    Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
    Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
    de Jong C et al., 2017, Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman., Br J Clin Pharmacol
    Drögemöller BI et al., 2017, Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer., JAMA Oncol
    Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics
    Hagleitner MM et al., 2014, Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts., PLoS One
    Carleton BC et al., 2014, Genetic markers of cisplatin-induced hearing loss in children., Clin Pharmacol Ther
    Lanvers-Kaminsky C et al., 2014, Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity., Clin Pharmacol Ther
    Yang JJ et al., 2013, The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer., Clin Pharmacol Ther
    Pussegoda K et al., 2013, Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children., Clin Pharmacol Ther
    Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet
    Bosia M et al., 2015, COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine., Pharmacogenomics
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Zivković M et al., 2013, The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol., J Clin Psychopharmacol
    Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
    Xu Q et al., 2016, Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population., Pharmacogenomics J
    Saiz-Rodríguez M et al., 2019, Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects., Basic Clin Pharmacol Toxicol
    Goudreau JL et al., 2002, Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease., Mov Disord
    Woo JM et al., 2002, Catechol O-methyltransferase genetic polymorphism in panic disorder., Am J Psychiatry
    Dauvilliers Y et al., 2002, Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil., Pharmacogenomics J
    Alsobrook JP 2nd et al., 2002, Association between the COMT locus and obsessive-compulsive disorder in females but not males., Am J Med Genet
    Ohara K et al., 1998, Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression., Neuroreport
    Li T et al., 1997, Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder., Pharmacogenetics
    Stein MB et al., 2005, COMT polymorphisms and anxiety-related personality traits., Neuropsychopharmacology
    Enoch MA et al., 2003, Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism., Psychiatr Genet
    Berrettini WH et al., 2007, Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence., Biol Psychiatry
    Taranu A et al., 2017, The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings., Basic Clin Pharmacol Toxicol
    Hopkins SC et al., 2013, Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder., Psychiatry Res
    Narasimhan S et al., 2012, Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder., Psychiatry Res
    Horowitz R et al., 2000, Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study., Am J Med Genet
    Vandenbergh DJ et al., 1997, High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers., Am J Med Genet
    Rakvåg TT et al., 2005, The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients., Pain
    Zubieta JK et al., 2003, COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor., Science
    Zhao QZ et al., 2012, Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study., Psychiatr Genet
    Fijal BA et al., 2009, Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia., Pharmacogenomics J
  • ENTACAPONE   COMT

    Interaction Score: 15.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name entacapone, Comtan
    Novel drug target Established target
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    21280081 11440283 12876237 12538800 10981253 10882160 11873938 10439935 9808337 11939936 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • TOLCAPONE   COMT

    Interaction Score: 14.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Catechol O-methyltransferase inhibitor

    PMIDs:
    18046910 19503773 20502133 10882160 11873938 15697329 9808337 11752352 17063156 12538800 9917075


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • OPICAPONE   COMT

    Interaction Score: 5.8

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    27498199 16690967


    Sources:
    TTD

  • REMIFENTANIL   COMT

    Interaction Score: 5.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130


    Sources:
    PharmGKB

  • SUFENTANIL   COMT

    Interaction Score: 3.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130


    Sources:
    PharmGKB

  • OXYCODONE   COMT

    Interaction Score: 2.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130


    Sources:
    PharmGKB

  • MODAFINIL   COMT

    Interaction Score: 1.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12465073 12359690 11990384 11840516 9631418 9352569 15956988 12605099


    Sources:
    PharmGKB

  • MORPHINE   COMT

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130 11054766 9259381 15927391 12595695


    Sources:
    PharmGKB

  • METHADONE   COMT

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32407152 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130


    Sources:
    PharmGKB

  • BENZTROPINE   COMT

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TRIHEXYPHENIDYL   COMT

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VENLAFAXINE   COMT

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28627776 23706899 22417933


    Sources:
    PharmGKB

  • BUPRENORPHINE   COMT

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30549211


    Sources:
    PharmGKB

  • METHYLPHENIDATE   COMT

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29230023 24763183 24035255 23131881 22149470 21550019 18703939 18214865


    Sources:
    PharmGKB

  • FLUVOXAMINE   COMT

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20619611


    Sources:
    PharmGKB

  • SUMATRIPTAN   COMT

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • NICOTINE   COMT

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26555332 22695756 18192898 16395295 11927842


    Sources:
    PharmGKB

  • FENTANYL   COMT

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30549211 30281924


    Sources:
    PharmGKB

  • BUPROPION   COMT

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16876132


    Sources:
    PharmGKB

  • PAROXETINE   COMT

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18989660


    Sources:
    PharmGKB

  • DIACETYLMORPHINE   COMT

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • QUETIAPINE   COMT

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26282453


    Sources:
    PharmGKB

  • CISPLATIN   COMT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28560854 28448657 28445188 25551397 25141953 24642735 23820299 23588304 19898482


    Sources:
    PharmGKB

  • RISPERIDONE   COMT

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22935916 19451915


    Sources:
    PharmGKB

  • SERTRALINE   COMT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • HALOPERIDOL   COMT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 23963056


    Sources:
    PharmGKB

  • NOREPINEPHRINE   COMT

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHYLDOPA   COMT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CLOZAPINE   COMT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25560469


    Sources:
    PharmGKB

  • LEVODOPA   COMT

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LITHIUM   COMT

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   COMT

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000093010

    • Version: 101_38

    Alternate Names:
    COMT Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P21964

    • Version: 01-August-2011

    Alternate Names:
    1312 Entrez Gene Id
    COMT_HUMAN Uniprot Id
    ENSG00000093010 Ensembl Gene Id

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 2.1.1.6

    Publications:

  • TdgClinicalTrial: P21964

    • Version: January-2014

    Alternate Names:
    COMT Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.1.1.6

    Publications:

  • PharmGKB: COMT

    • Version: 18-August-2020

    Alternate Names:
    PA117 PharmGKB ID

    Gene Info:

    Publications:
    Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry
    Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet
    Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics

  • ChemblInteractions: COMT

    • Version: chembl_23

    Alternate Names:
    COMT GENE_SYMBOL
    Catechol O-methyltransferase UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000093010

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000093010 Gene Symbol
    COMT Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TTD: Catechol-O-methyl-transferase

    • Version: 2020.06.01

    Alternate Names:
    COMT TTD Gene Abbreviation
    T76904 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21